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Long-term treatmentwith responsive brain
stimulation in adults with refractory partial
seizures
ABSTRACT
Objective: The long-term efficacy and safety of responsive direct neurostimulation was assessed
in adults with medically refractory partial onset seizures.
Methods: All participants were treated with a cranially implanted responsive neurostimulator that
delivers stimulation to 1 or 2 seizure foci via chronically implanted electrodes when specific elec-
trocorticographic patterns are detected (RNS System). Participants had completed a 2-year pri-
marily open-label safety study (n 5 65) or a 2-year randomized blinded controlled safety and
efficacy study (n 5 191); 230 participants transitioned into an ongoing 7-year study to assess
safety and efficacy.
Results: The average participant was 34 (611.4) years old with epilepsy for 19.6 (611.4) years.
The median preimplant frequency of disabling partial or generalized tonic-clonic seizures was
10.2 seizures a month. The median percent seizure reduction in the randomized blinded con-
trolled trial was 44% at 1 year and 53% at 2 years (p , 0.0001, generalized estimating equa-
tion) and ranged from 48% to 66% over postimplant years 3 through 6 in the long-term study.
Improvements in quality of life were maintained (p , 0.05). The most common serious device-
related adverse events over the mean 5.4 years of follow-up were implant site infection (9.0%)
involving soft tissue and neurostimulator explantation (4.7%).
Conclusions: The RNS System is the first direct brain responsive neurostimulator. Acute and sus-
tained efficacy and safety were demonstrated in adults with medically refractory partial onset
seizures arising from 1 or 2 foci over a mean follow-up of 5.4 years. This experience supports
the RNS System as a treatment option for refractory partial seizures.
Classification of evidence: This study provides Class IV evidence that for adults with medically
refractory partial onset seizures, responsive direct cortical stimulation reduces seizures and im-
proves quality of life over a mean follow-up of 5.4 years. Neurology® 2015;84:810–817
GLOSSARY
AE 5 adverse event; CI 5 confidence interval; DBS 5 deep brain stimulation; ECoG 5 electrocorticographic; LTT 5 Long-
Term Treatment; QOLIE-89 5 Quality Of Life In Epilepsy Inventory–89; SAE 5 serious adverse event; SUDEP 5 sudden
unexplained death in epilepsy; VNS 5 vagus nerve stimulation.
Stimulation therapies have demonstrated efficacy and safety as adjunctive treatments for med-
ically intractable partial onset seizures. The vagus nerve stimulator (VNS Therapy System,
Cyberonics, Houston, TX) provides scheduled (open-loop) stimulation to a peripheral nerve
and reduced partial seizure frequency by 24.5%–28% during the blinded period of
randomized controlled trials1,2 and demonstrated median seizure reductions in a prospective
open-label study of 35% at 1 year and 43% at 3 years.3,4 A randomized controlled trial of
scheduled deep brain stimulation (DBS) of the anterior nucleus of the thalamus showed reduc-
tions in partial seizures of 41% at 13 months and 56% at 26 months.5
The RNS System is the first responsive (closed-loop) focal cortical stimulator for use as an adjunc-
tive therapy indicated for adults (18 years or older, refractory to 2 or more antiepileptic drugs) having
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frequent and disabling partial onset seizures
localized to no more than 2 epileptogenic foci
by diagnostic testing. The RNS System was
approved by the US Food andDrug Administra-
tion6 in this patient population for reducing
seizure frequency based on a multicenter
double-blinded randomized sham-stimulation
controlled trial and an earlier feasibility study.7,8
This report is from an ongoing 7-year multi-
center prospective open-label study for partici-
pants who completed the feasibility or pivotal
studies in order to provide data on longer-
term safety and efficacy.
METHODS The RNS System (NeuroPace, Mountain View,
CA) provides responsive (closed-loop) stimulation directly to
1 or 2 seizure foci when abnormal electrocorticographic (ECoG)
activity is detected, typically epileptiform activity that has been
observed at the onset of electrographic seizures. A cranially im-
planted programmable neurostimulator is connected to depth or
subdural cortical strip leads that are surgically placed at 1 or 2 pre-
viously identified seizure foci. Each lead contains 4 electrode con-
tacts (figure 1). As many as 4 leads could be implanted in the
clinical trials (no more than 2 depth leads), although only 2 leads
can be connected to the neurostimulator at a time. The neurostim-
ulator continually senses ECoG activity through the electrodes and
is programmed by the physician to detect specific ECoG patterns
and deliver brief stimulus pulses in response to detections. The
physician adjusts detection and stimulation parameters for each
patient as needed for seizure reduction.9
The Long-Term Treatment (LTT) Study is an ongoing
7-year multicenter prospective open-label study to evaluate the
long-term efficacy and safety of the RNS System. Participants
had completed the feasibility or pivotal studies (figure 2). Adverse
event (AE) and daily seizure diary data were collected every 6
months at a minimum. Quality of life was assessed yearly by
the Quality Of Life In Epilepsy Inventory–89 (QOLIE-89).10
Antiepileptic medications were adjusted as medically necessary.
Efficacy was assessed as median percent change in seizures
and as responder rate (the percentage of participants with a
50% or greater reduction in seizures) for each 3-month period
compared to the preimplant baseline. Average changes in the
QOLIE-89 overall T score and primary scale T scores were com-
pared to the preimplant baseline using a paired t test.
An independent data monitoring committee reviewed all AEs
and a second committee determined whether deaths met criteria
for sudden unexplained death in epilepsy (SUDEP).
Standard protocol approvals, registrations, and patient
consents (IDE G030126). All study protocols were approved
by the institutional review boards of participating investigation
sites. All participants gave written informed consent. The studies
were registered on www.clinicaltrials.gov (NCT00572195).
All analyses include data up to November 1, 2013, with the
exception of data on deaths and SUDEP, which were as of July
15, 2014.
RESULTS A total of 256 participants were implanted
with the neurostimulator and leads and 230 of these
participants enrolled in the LTT Study. A total of 191
participants continued to participate as of this data
cutoff date, resulting in an accumulated experience
of 1,389 patient implant years and 1,293 patient
stimulation years. The mean and median follow-up
period was 5.4 patient implant years (SD 2.1 years,
range 5 weeks–9.6 years). Participant accountability
is provided in figure 2.
Participant demographics and clinical characteris-
tics are provided in table 1. Most participants had
experienced frequent seizures for many years. One-
third had been treated with vagus nerve stimulation
(VNS) or epilepsy surgery, and almost two-thirds
had been evaluated for epilepsy surgery with intracra-
nial electrodes.
Efficacy. Seizure reduction. The reduction in seizures in
participants treated with responsive neurostimulation
increased progressively over the first 2 years of treat-
ment and remained stable over years of follow-up
(table 2).
Results of the randomized, sham stimulation con-
trolled pivotal trial, which were previously reported,7,8
are summarized here. During the randomized blinded
period of the pivotal study (months 3 through 5 after
implant), the overall seizure reduction in the partici-
pants receiving active responsive stimulation (37.9%)
was greater than in the participants receiving sham
stimulation (17.3%) relative to baseline (p 5 0.012,
generalized estimating equation).7 In the first month of
the blinded period, seizure reduction in the treatment
group was 34.2%, increasing to 38.1% in the second
month and reaching 41.5% in the final month. Re-
ductions in seizures were similar in those with mesial
temporal and neocortical onsets, in those with 1 and 2
seizure onset foci, in patients with and without prior
intracranial monitoring, and in those treated and not
treated with VNS or with epilepsy surgery.1
During the open-label period of the pivotal study,
the median percent reduction in seizures was 44% at
1 year and 53% at 2 years postimplant, a significant
improvement over time (p , 0.0001).8 The reduc-
tion in seizures was similar in participants who had
changes in their antiseizure medications (n5 98) and
those who did not (n 5 88).8
The reduction in seizures continued over years of
follow-up in the LTT Study (table 2). The median
percent reduction in seizures was 60% at the begin-
ning of year 3, and 66% at the beginning of year 6.
The responder rates at the same time points were
58% and 59%, respectively. To assess possible enrich-
ment of the population due to participant withdrawals,
an adjusted responder rate was calculated, which
included all participants who had withdrawn due to lack
of efficacy or to pursue other treatments. The adjusted
responder rates for those same time points (years 3 and
6) were 58% and 56%, respectively (table e-1 on the
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Seizure frequency decreased in the majority of par-
ticipants treated with responsive stimulation. Based on
the most recent 3 months of available data for each par-
ticipant (a last observation carried forward analysis for
those with 3 complete months of data), 84% of partic-
ipants (207/247) had some improvement, 60% (146/
247) had a 50% or greater reduction (compared to 8%
[19/247] with a 50% or greater increase), and 16% of
participants (40/247) were seizure-free.
Some participants had extended periods of seizure
freedom. Over one-third (36.7%) of the 256 im-
planted participants had at least 1 seizure-free period
of 3 months or longer, 23.0% had at least 1 seizure-
free period of 6 months or longer, and 12.9% had at
least 1 seizure-free period of 1 year or longer. No par-
ticipants were seizure-free over the entire follow-up.
Antiseizure medications were frequently adjusted
during the open-label follow-up. Sixty-three percent
of the responders and 70% of the nonresponders had
a new antiseizure medication added, and 9% of the res-
ponders and 8% of the nonresponders had a reduction
in the number or dosage of antiseizure medications.
Quality of life. Quality of life improved at 1 year
postimplant (n 5 214, average 5 13.26, SD 5
8.54, p , 0.001) and improvements were maintained
through year 5 (n 5 147, average 5 12.15, SD 5
10.75, p , 0.01). To assess for possible enrichment of
the population due to participant withdrawals, the
change from baseline was calculated by using a last
observation carried forward analysis for those partici-
pants who withdrew due to lack of efficacy or to pursue
other treatments. The improvement from baseline re-
mained statistically significant through year 4 (p ,
0.001) and there was a trend toward significance at year
5 (p 5 0.061). After 5 years, the sample sizes were not
sufficient to reliably assess statistical significance. Im-
provements were also seen on the QOLIE-89 primary
scales of attention, health discouragement, language,
memory, overall quality of life, seizure worry, and work
and social function (p , 0.05). There were no trends
toward declines in any primary scale score (QOLIE data
available in table e-2).
Safety. Over all studies, serious AEs (SAEs) were pri-
marily anticipated events related to an implanted
device or to seizures, and because of hospitalizations
for video EEG monitoring. SAEs that occurred in
2.5% or more of the participants at any time after
implant are provided in table 3.
SAEs of particular concern with any implanted
medical device or in persons with epilepsy were con-
sidered in detail. SAEs related to any type of intracra-
nial hemorrhage occurred in 4.7% of participants
(12) and the majority of these were in the first days
after the initial implant (2 participants with an epidu-
ral hematoma, 1 with a subdural hematoma, and
1 with a CT-diagnosed asymptomatic intraventricular
hemorrhage), or were associated with seizure-related
head trauma (3 participants with subdural hemato-
mas, 1 with a subarachnoid hemorrhage, and 1 with
a traumatic intracranial hemorrhage). There were
no neurologic sequelae. There were 3 postoperative
intracranial hemorrhages that were not related to
Figure 1 Implanted RNS neurostimulator and NeuroPace cortical strip and
depth leads
Copyright owned by NeuroPace, Inc; no permissions for use are required.
Figure 2 RNS System studies: Participant accountability
a Six participants discontinued before completing the study; 2 participants completed the
study, but elected not to enroll in the Long-Term Treatment (LTT) Study. b Fourteen partic-
ipants discontinued prior to completing the study; 4 participants completed the study, but
elected not to enroll in the LTT Study. c Discontinuation reasons: to pursue other treatments
(9); insufficient efficacy (5); participant chose not to replace neurostimulator after expected
battery depletion (5) or after resolution of infection (4); noncompliance (3); elective explant
(1); ongoing suicidality/noncompliance (1). d Study ongoing; data as of November 1, 2013.
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seizures. One participant with 3 cortical strip leads
had a cerebral hemorrhage in year 3 postimplant
and had mild right hand paresis; this participant
had the neurostimulator and leads explanted 18
months later. The second participant had 2 depth
and 2 cortical strip leads and had a subtemporal
hematoma 2.5 years after implant that led to an exac-
erbation of a preexisting memory deficit. The third
participant had 4 cortical strip leads and experienced
a cerebral hemorrhage 2.8 years after implant that
caused a persistent headache. Both the second and
third participants continued to be treated with
responsive stimulation.
All implant site infections or erosions leading to an
SAE were superficial soft tissue infections. Five partic-
ipants (2.0%) had a postoperative implant site infec-
tion; one of these 5 participants had the
neurostimulator and leads explanted. After the postop-
erative period, 20 participants (including one of the 5
participants who had a postoperative infection) had
an SAE related to a soft tissue implant site infection;
2 of these were attributed to seizure-related head
trauma, and the remainder followed a neurostimulator
replacement. All participants were treated with
antibiotics; 2 participants had their neurostimulator re-
placed, 14 had the neurostimulator explanted (10 par-
ticipants also had the leads explanted), and 2
participants were later reimplanted. There were no in-
fections of the brain or subdural space, no sepsis, and
no long-lasting neurologic or medical consequences.
Other SAEs reported in 2.5% or more of the par-
ticipants were related to changes in seizures that were
considered serious because the participant was admit-
ted to the hospital for observation or for IV antisei-
zure medication. None of these events occurred
with initiation of stimulation and no participant
withdrew from any of the studies because of a
seizure-related SAE.
There were 11 deaths: 2 by suicide in patients with
a history of depression (1 that occurred when respon-
sive stimulation was off), 1 due to status epilepticus in
a participant who had subtherapeutic levels of antisei-
zure medications, and 1 due to lymphoma. Seven of
the 11 deaths were attributed to possible, probable,
or definite SUDEP; 2 occurred while responsive stim-
ulation was off. The rate of probable or definite SU-
DEP for participants implanted with the RNS System
was 3.5 per 1,000 patient implant years (confidence
interval [CI] 1.5–8.5) and 2.6 per 1,000 patient stim-
ulation years (CI 1.0–7.0).
DISCUSSION Responsive (closed-loop) neurostimu-
lation is a new approach to treating epilepsy. Stimu-
lation is delivered to the seizure focus in response to
epileptiform activity. Similar to adjusting the dose
of an antiseizure medication to maximize efficacy
and tolerability, detection and stimulation parameters
can be adjusted to improve clinical benefits and avoid
stimulation-related adverse events.
In the most general sense, epilepsy is a disorder in the
balance of excitation and inhibition. In partial epilepsy,
the disturbance may be well-localized, but electrical
activity spreads monosynaptically and polysynaptically
to other regions to create the symptoms of the clinical
seizure. The objective of responsive neurostimulation
is to identify the critical region or propagation pathways
and to then provide neutralizing, disruptive, or driving
activity in order to restore normal function.11
Treatment with the RNS System provided a signifi-
cant and sustained reduction in seizures and improved
quality of life in adults with many years of partial onset
seizures that were resistant to multiple antiseizure med-
ications and in many cases to VNS or epilepsy surgery.
A double-blinded randomized controlled study of
the RNS System as an adjunctive treatment for adults
with medically intractable partial seizures arising from
1 or 2 seizure foci1,8 demonstrated a progressive
reduction in seizures from implant through the sec-
ond year after implant. These interim results of a
prospective open-label long-term study indicate that
Table 1 Participant demographics and characteristics (all implanted
participants n 5 256)
Characteristics Values
Female, % (n) 49 (125/256)
Age, y,a mean 6 SD (range) 34.0 6 11.4 (18–66)
Duration of epilepsy, y,a mean 6 SD (range) 19.6 6 11.4 (2–57)
Current number of antiseizure medications,a
mean 6 SD (range)
2.9 6 1.1 (0–8)
Preimplant frequency of simple partial motor,
complex partial, and secondarily generalized tonic-clonic
seizures per month, mean, 6 SD (range); median
50.7 6 177.4 (0–2,320)b; 10.2
Prior intracranial monitoring, % (n) 65 (166/256)
Prior epilepsy surgery, % (n) 34 (86/256)
Prior vagus nerve stimulation, % (n) 32 (82/256)
Two seizure foci (vs 1), % (n) 48 (124/256)









Mesial as well as neocortical onset, % (n) 7.4 (19/256)
a At enrollment in originating study.
bOne participant in the feasibility study had only simple partial sensory seizures, which
were not included in the analysis of disabling seizures.
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the median percent seizure reduction is sustained at
60% or greater over additional years of follow-up.
The majority of participants benefitted from treat-
ment with the RNS System, and 23% experienced
at least one 6-month period of seizure freedom.
Increased efficacy over the first 1–2 years of stimu-
lation therapy is reported with other devices for treat-
ment of partial onset seizures such as VNS4,12 and DBS
of the anterior nucleus of the thalamus.6 In addition,
progressive improvement in the therapeutic response
has been observed with stimulation of the anterior cin-
gulate cortex for depression,11 subthalamic nucleus,
anterior limb of the internal capsule, and nucleus ac-
cumbus for obsessive-compulsive disorder,13 and glo-
bus pallidus for primary dystonia.14
The observations of an acute and delayed therapeu-
tic effect of brain stimulation suggest multiple mecha-
nisms of action.11 Acute effects of stimulation could
be related to changes in cellular inhibition or excitation,
to changes in cerebral blood flow, or to axonal and glial
release of neurotransmitters.15–18 Changes in synaptic
plasticity, neurogenesis, or cortical reorganization may
be responsible for the effects over time.11,19,20 Respon-
sive neurostimulation can adapt to these dynamic phys-
iologic changes, which might offer an advantage over
nonresponsive, scheduled, or continuous stimulation.
Responsive neurostimulation was well-tolerated
and safe over time and adverse events related to the
implanted device, including hemorrhage and infection,
were anticipated and the rates were not higher than re-
ported with implantation of intracranial electrodes to
localize the seizure focus21–23 and with epilepsy sur-
gery,21,24,25 or with DBS devices for treatment of move-
ment disorders.26 The number of seizure-related adverse
events was not higher than in randomized controlled
trials of medications for adjunctive treatment of partial
onset seizures.27–30 Deaths, including deaths by SUDEP,
were not more frequent than is expected in patients with
medically intractable partial onset seizures.31,32
The Institute of Medicine33 concluded that at least
30% of adults with partial onset seizures27,28 do not
achieve seizure control with antiepileptic medications
and a similar percentage have significant medication-
related side effects.27,28,34,35 Some of these patients will
consider epilepsy surgery or a vagus nerve stimulator.
However, not all patients are candidates for these treat-
ments and these treatments do not always provide
Table 3 Serious adverse events affecting
‡2.5% of implanted participants
(1,389 patient implant years with mean




Implant site infection 9.4 (24)
Complex partial seizures increased 7.8 (20)
EEG monitoringa 7.2 (44)









Premature battery depletiond 4.3 (11)
Device lead damage 3.5 (9)
Depression suicidal 3.1 (8)
Device lead revision 3.1 (8)
Nonconvulsive status epilepticus 3.1 (8)
Pneumonia 3.1 (8)
Convulsive status epilepticus 2.7 (7)
Skin laceration (due to seizure) 2.7 (7)
Suicide attempt 2.7 (7)
Study ongoing; data as of November 1, 2013.
aConsidered a serious adverse event due to admission to
an epilepsy monitoring unit.
b Led to hospital admission in all 18 participants; 16 due to
antiseizure medication toxicity.
c Pursue other treatments (8), insufficient efficacy (4),
participant elected (2).
dOccurred with battery from manufacturer that is no
longer in use.








Months 36–38 214 60.0 (24.2, 85.8) 57.9 (51.3–64.4)
Months 39–41 216 57.2 (21.4, 86.0) 56.0 (49.4–62.5)
Months 42–44 212 62.1 (27.8, 89.7) 59.9 (53.2–66.3)
Months 45–47 208 65.9 (33.2, 88.5) 60.6 (53.8–67.0)
Year 4
Months 48–50 204 63.3 (29.8, 91.2) 60.8 (53.9–67.2)
Months 51–53 202 62.2 (25.1, 89.6) 62.4 (55.5–68.8)
Months 54–56 196 64.8 (21.5, 88.1) 60.7 (53.7–67.3)
Months 57–59 197 61.8 (23.8, 88.9) 61.4 (54.5–67.9)
Year 5
Months 60–62 172 65.5 (23.2, 91.2) 61.0 (53.6–68.0)
Months 63–65 161 60.7 (21.4, 91.6) 60.9 (53.2–68.1)
Months 66–68 142 62.4 (25.0, 92.2) 59.9 (51.6–67.6)
Months 69–71 117 48.1 (14.8, 86.2) 49.6 (40.7–58.5)
Year 6
Months 72–74 115 65.7 (30.6, 87.1) 59.1 (50.0–67.7)
aNo. represents participants who have reached that time point in the ongoing study.
b The 95% confidence interval was calculated using the Wald method.
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meaningful benefit. New treatments are needed that can
provide better seizure control and are well-tolerated.
The clinical meaningfulness of the response to
treatment with the RNS System is supported by sig-
nificant improvements in overall quality of life and in
individual domains that indicate a more positive per-
ception of cognitive function, relationships and social
function, overall health, and vulnerability to seizures.
These are areas of function that are often profoundly
impacted in persons with intractable seizures.33,36–38
Retention rate is an important metric of patient
satisfaction and is a clinically meaningful composite
of efficacy and safety.39 In the RNS System studies,
the majority of participants chose to continue treat-
ment, indicating that treatment was perceived to be
of benefit. The 1-year discontinuation rate was 3.9%,
whereas 1-year discontinuation rates in trials of
approved antiseizure medications range from 23% to
77%.40,41 Ninety-seven percent of patients chose to
continue treatment by enrolling into the LTT Study.
Discontinuation of treatment simply required that the
neurostimulator be programmed off since all compo-
nents of the device may be left in place. These rates
compare favorably to retention rates in trials of other
approved epilepsy therapies, including VNS and anti-
seizure medications. The majority of discontinuations
in antiseizure medication trials are due to medication-
related side effects such as cognitive and behavioral side
effects, and other AEs such as nausea, sedation, dizziness,
and rash (55%–77%).39 These types of adverse events
were not commonwith treatment with the RNS System.
There are limitations to any open-label study.
Potential confounds include a regression from a higher
than usual baseline seizure frequency to a more typical
frequency during the treatment period. The partici-
pant and physician may have a positive bias towards
therapeutic efficacy. However, these are unlikely to
explain the seizure reduction over years in patients
who have failed many treatment trials.
The RNS System is the first device that provides
responsive neurostimulation and has shown acute
and sustained efficacy, tolerability, and safety in adults
with medically intractable partial onset seizures. Future
research and clinical experience will provide additional
understanding about patient selection, stimulation
targets, and stimulation parameters. Fundamental
research into the mechanisms of action of brain stimu-
lation will facilitate its clinical application. The accu-
mulated experience demonstrates that responsive
neurostimulation provides another treatment option
for patients with medically intractable partial onset seiz-
ures who are not good candidates for epilepsy surgery.
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